Genprex (GNPX) Other Non-Current Liabilities (2025 - 2026)

Genprex (GNPX) posted quarterly Other Non-Current Liabilities of $22500.0 for Q1 2026, little changed quarter-over-quarter from $22500.0 in Q4 2025.

Genprex (GNPX) Other Non-Current Liabilities (2025 - 2026) Analysis & Trends

Genprex's Other Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $22500.0 for Q1 2026.

In Q1 2026, Other Non-Current Liabilities changed N/A year-over-year to $22500.0; the TTM figure through Mar 2026 stood at $22500.0 (changed N/A YoY), while the FY2025 annual figure was $22500.0, changed N/A from the prior year.
Other Non-Current Liabilities for Q1 2026 stood at $22500.0, roughly flat from $22500.0 in the prior quarter.
The five-year high for Other Non-Current Liabilities was $243000.0 in Q3 2025, with the low at $22500.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Genprex	1.88 Mn	-13.28 Mn	-

Download Data